PRESCIENT THERAPEUTICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.044 AUD | -4.35% |
|
0.00% | -29.03% |
| 25/03 | Transcript : Prescient Therapeutics Limited - Special Call | |
| 23/02 | Prescient Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Presenter SpeechWarrick Lace (Executives)Okay. Good afternoon, everyone. Let's make a start. W...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.
Calendar
26/08/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -29.03% | 24.59M | |
| +64.92% | 62.59B | |
| -1.85% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +13.05% | 26.21B | |
| -21.96% | 19.09B | |
| +4.21% | 13.08B | |
| +25.74% | 12.26B | |
| +27.42% | 12.05B |
- Stock Market
- Equities
- PTX Stock
- News Prescient Therapeutics Limited
- Transcript : Prescient Therapeutics Limited - Special Call
